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Non-steroidal anti-inflammatory drugs (NSAIDs) are used against pain, fevers of 
various origins and inflammation. Although they are widely prescribed throughout 
the world, many of them are associated with side effects. These drugs are often 
used in self-medication as their purchase is also unrestricted over the Internet. The 
risk of administration of uncontrolled medicines is thus naturally greater. 
Furthermore, NSAIDs are often subject to the practice of counterfeit medicines, 
which is gaining increasing momentum in the world and particularly in emerging 
countries where unimaginable proportions rising up to 80 % of counterfeit have 
been reported. This has adverse consequences for public health.  
2. Objectives 
q  To develop a generic analytical method by means of an experimental design combined 
to a novel Design Space (DS) optimization strategy using Liquid Chromatography with UV 
detection. 
q  To demonstrate the robustness of the developed method (transfer HPLC to UHPLC). 
q  To validate the developed methods and apply them in analysis of real samples. 
27 molecules were selected, including 18 NSAIDs, 3 molecules often associated with 
NSAIDs, 1 degradation product and 5 preservatives. These molecules were divided into 5 
groups on basis of the pharmaceutical form of the NSAIDs. 
Group 2 includes the compounds presented in syrup and suspension  (paracetamol (PAR), 
Na-benzoate (BEN), nipagine (NIP), nipasol (NIS), nimesulide (NIM), butylated 
hydroxyanisole (BHA), ibuprofen (IBU), mefenamic acid (MA) and butylated hydroxy-
toluene (BHT). Group 4 includes  the pharmaceutical combinations presented in tablet or 
capsule (paracetamol, ibuprofen and caffeine (CAF), etc.). 
3. Optimisation and prediction 
Three factors (Table 1) previously selected after a screening phase were 
tested and studied with regards to the chromatographic behavior of analytes 
(with the logarithm of the retention factors being selected as chromato-
graphic responses) [B. Debrus et al., Anal. Chim. Acta. 691 (2011) 33]. 
Table 1 : Selected factors and their levels for the optimization of the LC conditions 
Factors Levels 
pH 1.85 2.42 3.14 4.42 5.71 6.42 7.00 
Gradient time (TG, min) - 20.0 24.5 40.0 55.5 60.0 - 
Temperature (T°, °C) - 20.0 21.7 27.5 33.3 35.0 - 
An experimental central composite design custom was applied while 
modeling all peak responses  by means of  equation 1. 
 
Log(k) = β0 + β1.pH + β2.pH2 + β3.pH3 + β4.pH4+ β5.TG + β6.TG2 + β7.To + 
β8.To2 + β9.pH.TG + β10.pH.To + β11.To.TG + β12.pH.To.TG + ε (Eq.1) 
 
with k the retention factor (k = (tR-t0)/t0). Logarithms of peak half-widths 
were also modeled by equation 1. Each analyte’s chromatographic behavior 
was independently modeled by a set of 3 equations, for the retention factor 
and for left and right half-widths.  
Models were adjusted through a stepwise regression and were found 
excellent (R2 adjusted > 0.99) meaning that the responses were correctly 
modeled. Residuals were normally distributed, mostly between -1 and 1 
min. The Design Space (DS), which defines the multidimensional sub-
region in which the probability that a criterion reaches the preset threshold 
is greater than a selected quality level, was calculated using equation 2. 
(Eq. 2) 
Figures 1 : DS for group 2 with the white region including the minimum  
quality level π = 95% 
§  The DS shapes depicted in Figures 1 show broad regions with respect to 
variations in TG [40, 60] min, in T° [20, 35]°C and in pH [3.90, 4.30]. 
§  These broad regions are key results as they represent robustness of the 
operating conditions if quality level is high, indicating guarantees of quality 
for future use of the methods. 
4. Demonstration of the robustness  
Figures 2 : Chromatograms of the developed 
method under predicted computed conditions 
(A) and with HPLC (B) and UHPLC (C) 
equipments. 
RRT for predicted conditions and those 
obtained with HPLC and UHPLC were close. 
Similar results were obtained for the 
remaining groups demonstrating the adequa-
te geometric transfer of the methods. 
Moreover, the transfer results show that the 
variability due to the transfer did not 
decrease the chromatographic separation 
efficiency.  
LC conditions :  Analytical  column : Xbrigde 250 x 4.6 mm; i.d., dp=5 µm).  
Mobile phase : mixture of methanol  and  20mM  NH4-Formate buffer (pH 4.05).  
Gradient increased linearly methanol proportion from 15% to 95% in 53.14 
minutes.  
Flow rate: 1.0mL.min -1, column T°: 23°C. UV-detection: 220 nm 
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Compound Predicted RRT  Observed RRT  (HPLC) 
Observed RRT 
(UHPLC) 
PAR 0.141 0.146 0.150 
BEN 0.369 0.406 0.396 
NIP 0.446 0.447 0.438 
NIS 0.659 0.662 0.657 
NIM 0.682 0.682 0.680 
BHA 0.749 0.750 0.743 
IBU 0.850 0.854 0.849 
MA 0.904 0.910 0.908 
BHT 1.000 1.000 1.000 
Table 2 : Results of  the transfer from HPLC to 
UHPLC for group 2 and considering the relative 
retention times (RRT). 
The optimized HPLC methods were transferred to UHPLC with very satisfying results. An 
illustration is given for group 2 (Figures 2 and Table 2). 
5. Validation 
The developed methods were validated according to the total error strategy using the 
accuracy profile as decision tool [Ph Hubert et al., J. Pharm. Biomed. Anal. 45 (2007) 
82]. An illustration is given for group 4 (Figures 3). 
Figures 3 : Accuracy profiles for the molecules of group 4 and for 4-aminophenol  
(a degradation product of PAR). 
Legend 
 (—) : Relative bias (%). 
 (••••••) : Acceptance limits (5%). 
 (---) : Beta-expectation tolerance interval (95% ). 
 (●) : Relative error of the back-calculated individual measurement. 
§  For 4-aminophenol, a one –
level calibration was used: 0.1% 
(0.5 µg/mL) in 100% of PAR 
(500 µg/mL). 
§  All validation criteria 
recommended by ICH Q2(R1) 
(trueness, precision, accuracy) 
were simultaneously tested by 
means of the applied strategy. 
§  Since the Beta-expectation 
tolerance intervals or limits (for 
4-aminophenol) are included 
within the acceptance limits 
(Figures 3), one can conclude 
that the method is suitable for 
the quantification purpose.  
6. Application 
Table 3 : Assay results of five pharmaceuticals brands marketed in DRC 
The validated method was applied to the identification and the assay of PAR,  CAF 
and IBU. As a real case, five different brands of pharmaceutical drugs were tested. 
They were purchased in capsule form in D.R. Congo (DRC) and were mainly from 
Indian origin. The five drugs contained the three active ingredients but as shown in 
Table 3, most of the products were in one way or another non-compliant  to the 
specifications of EMA (95.0 – 105.0%). 
Coded specialties 
(Brands)  
Declared amount  
Content  obtained (mean % ± SD; n = 3) 
PAR CAF IBU 
A 
325 mg ;  30 mg 200 mg 
98.4 ± 0.41 % 90.7 ± 1.49 % 103.7 ± 0.74 % 
B 
325 mg 40 mg 200 mg 
100.0 ± 0.35 % 94.7 ± 0.63 % 103.0 ± 0.58 % 
C 
200 mg 
90.4 ± 0.22 % 
40 mg 
85.2 ± 0.79 % 
400 mg 
91.1 ± 0.73 % 
D 
325 mg 
78.2 ± 0.39 % 
40 mg 
74.5 ± 0.44 % 
400 mg 
77.9 ± 0.15 % 
E 
325 mg 40 mg 400 mg 
78.9 ± 0.28 % 75.9 ± 0.31 % 80.6 ± 0.35 % 
q  The use of experimental design allowed us to optimize simultaneously three selected factors including T°, pH and TG. This led to the development of HPLC methods for 
screening NSAIDs. 
q  The DS strategy enabled robust method development, confirmed by a successful method transfer from HPLC to UHPLC. The validated method can easily be used in 
quality control laboratories in emerging countries. 
q  The  results obtained during routine testing confirmed that the phenomenon of poor quality medicines remains a major public health problem. 
7. Conclusion 
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UHPLC conditions: Analytical column: 
Acquity BEH (50 mm × 2.1 mm i.d.,   
dp = 1.7 µm).  
Flow rate: 0.613 µL.min-1. 
